<DOC>
	<DOC>NCT01707147</DOC>
	<brief_summary>The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.</brief_summary>
	<brief_title>A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Study Design: PMS Observational study</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: Patients who have been started on Trajenta in accordance with the approved label in Korea Patients who have signed on the data release consent form Exclusion criteria: Patients with previous exposure to Trajenta and current participation in clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>